Noida Chronicle

Coronary Artery Disease Pipeline Analysis Demonstrates Novel 30+ Companies at the Horizon Expected to Transform the Treatment Paradigm

 Breaking News
  • No posts were found

Coronary Artery Disease Pipeline Analysis Demonstrates Novel 30+ Companies at the Horizon Expected to Transform the Treatment Paradigm

March 21
05:13 2023
Coronary Artery Disease Pipeline Analysis Demonstrates Novel 30+ Companies at the Horizon Expected to Transform the Treatment Paradigm

DelveInsight’s, “Coronary Artery Disease Pipeline Insight 2023” report provides comprehensive insights about 30+ Coronary Artery Disease companies and 30+ pipeline drugs in the Coronary Artery Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. The Coronary Artery Disease pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Coronary Artery Disease Emerging drugs, the Coronary Artery Disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Coronary Artery Disease pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Coronary Artery Disease Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Coronary Artery Disease clinical trials studies, Coronary Artery Disease NDA approvals (if any), and product development activities comprising the technology, Coronary Artery Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Coronary Artery Disease Pipeline Report

 

  • DelveInsight’s Coronary Artery Disease pipeline analysis depicts a robust space with 30+ active players working to develop 30+ pipeline treatment therapies.

 

  • The leading Coronary Artery Disease Companies include Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, GE Healthcare, Honya Medical Inc, Novartis Pharmaceuticals, and others.

 

  • Promising Coronary Artery Disease Pipeline Therapies include Selatogrel, XTR 003, AdVEGFXC1, Revacept, XTR004, MCRcI stem cells, PET MPI, Inclisiran, AZD-5718, VM202, Evolocumab, Ad5-FGF4, REG-101, and others.

 

  • The Coronary Artery Disease companies and academics are working to assess challenges and seek opportunities that could influence Coronary Artery Disease R&D. The therapies under development are focused on novel approaches to treat/improve Coronary Artery Disease.

 

Request a sample and discover the recent breakthroughs happening in the Coronary Artery Disease Pipeline landscape @ Coronary Artery Disease Pipeline Outlook Report

 

Coronary Artery Disease Overview

Coronary artery disease (CAD) is the most common type of heart disease in the United States. It is sometimes called coronary heart disease or ischemic heart disease. Coronary Artery Disease is caused by plaque buildup in the walls of the arteries that supply blood to the heart (called coronary arteries) and other parts of the body.Plaque is made up of deposits of cholesterol and other substances in the artery. Plaque buildup causes the inside of the arteries to narrow over time, which can partially or totally block the blood flow.

 

Recent Developmental Activities in the Coronary Artery Disease Treatment Landscape

 

  • In June 2022, Idorsia announced the subcutaneous administration of selatogrel by a healthcare professional has been studied in two Phase II clinical studies in patients with stable coronary artery disease (CAD) and in patients with AMI.

 

  • In February 2022, Regio Biosciences (Regio) entered into an exclusive license agreement with AstraZeneca to further develop REG-101, a novel therapeutic acting on reverse cholesterol transport (RCT). Under the terms of the agreement, AstraZeneca will provide an exclusive license to Regio for further development of REG-101, previously known as MEDI5884, to address patients with high unmet medical needs, including PAD and cardiovascular disease.

 

  • In March 2021, XyloCor Therapeutics raised $22.6 million to study a gene therapy designed to deliver VEGF to heart cells. The funding to support a clinical trial to assess the use of the VEGF gene therapy, XC001, to boost the effectiveness of CABG, a surgical procedure that treats coronary heart disease by diverting blood around narrowed or clogged arteries. 

 

For further information, refer to the detailed Coronary Artery Disease Drugs Launch, Coronary Artery Disease Developmental Activities, and Coronary Artery Disease News, click here for Coronary Artery Disease Ongoing Clinical Trial Analysis

 

Coronary Artery Disease Emerging Drugs Profile

 

  • Selatogrel:  Idorsia Pharmaceuticals

Selatogrel, is a small molecule being developed by Idorsia Pharmaceuticals. It acts as a P2Y12 receptor antagonist. Currently, the drug is being studied in Phase II stage of Clinical trial evaluation for the treatment of Coronary artery disease.

 

  • Atuliflapon: AstraZeneca

Atuliflapon (formerly AZD 5718) is an orally available, small molecule, 5-lipoxygenase activating protein inhibitor, being developed by AstraZeneca. Currently, the drug is being studied in Phase II stage of clinical trial evaluation for the treatment of Coronary artery disease.

 

  • XTR 003: Sinotau Pharmaceuticals

XTR003 is a PET imaging radiopharmaceutical agent used to trace myocardial fatty acid metabolism. XTR003 is a modified fatty acid that enters the myocytes and passes through mitochondrial membrane by the same process as the natural existing fatty acids and then undergoes partial β-oxidation before being trapped in the mitochondria. In preclinical study XTR003 showed high myocardial uptake and retention. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Coronary Artery Disease.

 

Coronary Artery Disease Pipeline Therapeutics Assessment

There are approx. 30+ key Coronary Artery Disease companies which are developing the therapies for Coronary Artery Disease. The companies which have their Coronary Artery Disease drug candidates in the most advanced stage, i.e. Phase II include, Idorsia Pharmaceuticals.

 

Find out more about the Coronary Artery Disease Pipeline Segmentation, Therapeutics Assessment, and Coronary Artery Disease Emerging Drugs @ Coronary Artery Disease Treatment Landscape

 

Scope of the Coronary Artery Disease Pipeline Report

 

  • Coverage: Global

  

  • Coronary Artery Disease Companies: Idorsia Pharmaceuticals, AstraZeneca, Sinotau Pharmaceuticals, XyloCor Therapeutics, AdvanceCor, Sinotau Pharmaceuticals, Honya Medical Inc, Novartis Pharmaceuticals, AstraZeneca, Helixmith, Amgen, Angionetics, Xylocor Therapeutics, and others.

 

  • Coronary Artery Disease Pipeline Therapies: Selatogrel, XTR 003, AdVEGFXC1, Revacept, XTR004, MCRcI® stem cells, PET MPI, Inclisiran, AZD-5718, VM202, Evolocumab, Ad5-FGF4, and others

 

  • Coronary Artery Disease Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Coronary Artery Disease Pipeline Companies and Therapies, click here @ Coronary Artery Disease Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Coronary Artery Disease: Overview
  4. Coronary Artery Disease Pipeline Therapeutics
  5. Coronary Artery Disease Therapeutic Assessment
  6. Coronary Artery Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug Name: Company Name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Selatogrel:  Idorsia Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. XTR 003: Sinotau Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Coronary Artery Disease Products
  20. Coronary Artery Disease Key Companies
  21. Coronary Artery Disease Key Products
  22. Coronary Artery Disease- Unmet Needs
  23. Coronary Artery Disease- Market Drivers and Barriers
  24. Coronary Artery Disease- Future Perspectives and Conclusion
  25. Coronary Artery Disease Analyst Views
  26. Coronary Artery Disease Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Coronary Artery Disease Mergers and acquisitions, Coronary Artery Disease Licensing Activities @ Coronary Artery Disease Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/